Inhibition of P-Glycoprotein by HIV Protease Inhibitors Increases Intracellular Accumulation of Berberine in Murine and Human Macrophages

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zha, Weibin ^a,b   Wang, Guangji ^b   Xu, Weiren ^c   Liu, Xuyuan ^c,d   Wang, Yun ^a   Zha, Beth S ^a   Shi, Jian ^b   Zhao, Qijin ^b   Gerk, Phillip M ^a   Studer, Elaine ^a   Hylemon, Phillip B ^a,e   Pandak, William M ^e   Zhou, Huiping ^a,e,f  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; BERBERINE; BROMSULFOPHTHALEIN; DIGOXIN; HALOPERIDOL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; RITONAVIR; VERAPAMIL;

ARTICLE; CELL CULTURE; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MACROPHAGE; MOLECULAR DOCKING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RISK FACTOR; WILD TYPE;

EID: 84872811617     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054349     Document Type: Article

References (48)

1. Pao V, Lee GA, Grunfeld C, (2008) HIV therapy, metabolic syndrome, and cardiovascular risk. Curr Atheroscler Rep 10: 61-70.
2. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB, (2005) HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 68: 690-700.
3. Zhou H, Jarujaron S, Gurley EC, Chen L, Ding H, et al. (2007) HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis 195: e134-143.
4. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, et al. (2005) Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors Author. Mol Pharmacol 67: 1909-1919.
5. Chen L, Jarujaron S, Wu X, Sun L, Zha W, et al. (2009) HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages Author. Biochem Pharmacol 78: 70-77.
6. Zhou H, Gurley EC, Jarujaron S, Ding H, Fang Y, et al. (2006) HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol 291: G1071-1080.
7. Huang J, Zhou H, Mahavadi S, Sriwai W, Lyall V, et al. (2005) Signaling pathways mediating gastrointestinal smooth muscle contraction and MLC20 phosphorylation by motilin receptors. Am J Physiol Gastrointest Liver Physiol 288: G23-31.
8. Zhu XZ, Li XY, Liu J, (2004) Recent pharmacological studies on natural products in China. Eur J Pharmacol 500: 221-230.
9. Kuo CL, Chi CW, Liu TY, (2004) The anti-inflammatory potential of berberine in vitro and in vivo Author. Cancer Lett 203: 127-137.
10. Wang Y, Xiao J, Zhou H, Yang S, Wu X, et al. (2011) A Novel Monocarbonyl Analogue of Curcumin, (1E,4E)-1,5-Bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, Induced Cancer Cell H460 Apoptosis via Activation of Endoplasmic Reticulum Stress Signaling Pathway. J Med Chem 54: 3768-3778.
11. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, et al. (2012) Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 19: 861-867.
12. Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, et al. (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296: E812-819.
13. Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, et al. (2009) Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296: E955-964.
14. Amasheh M, Fromm A, Krug SM, Amasheh S, Andres S, et al. (2010) TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling. J Cell Sci 123: 4145-4155.
15. Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y, et al. (2011) Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS One 6: e25436.
16. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
17. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY, (2002) The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 91: 193-197.
18. Maeng HJ, Yoo HJ, Kim IW, Song IS, Chung SJ, et al. (2002) P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci 91: 2614-2621.
19. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, et al. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289-294.
20. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, et al. (1999) Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16: 1206-1212.
21. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, et al. (2009) P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 32: 1588-1593.
22. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J, (2007) Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73: 1573-1581.
23. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ, (2000) Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. Aids 14: 1287-1289.
24. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, et al. (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87: 1023-1036.
25. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ, (2007) Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 59: 947-953.
26. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, et al. (2004) Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 26: 322-330.
27. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, et al. (2006) Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46: 758-767.
28. Moreau A, Le Vee M, Jouan E, Parmentier Y, Fardel O, (2011) Drug transporter expression in human macrophages. Fundam Clin Pharmacol.
29. Roy KR, Arunasree KM, Dhoot A, Aparna R, Reddy GV, et al. (2007) C-Phycocyanin inhibits 2-acetylaminofluorene-induced expression of MDR1 in mouse macrophage cells: ROS mediated pathway determined via combination of experimental and In silico analysis. Arch Biochem Biophys 459: 169-177.
30. Zha W, Liang G, Xiao J, Studer EJ, Hylemon PB, et al. (2010) Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages. PLoS One 5: e9069.
31. Lei B, Zha W, Wang Y, Wen C, Studer EJ, et al. (2010) Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction Author. Mol Pharm 7: 844-853.
32. Zhang J, Zhou F, Wu X, Gu Y, Ai H, et al. (2010) 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb-drug interactions. Drug Metab Dispos 38: 2179-2187.
33. Patel J, Buddha B, Dey S, Pal D, Mitra AK, (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11: 262-277.
34. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J, (2001) Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDS 15: 159-167.
35. He SM, Li CG, Liu JP, Chan E, Duan W, et al. (2010) Disposition pathways and pharmacokinetics of herbal medicines in humans. Curr Med Chem 17: 4072-4113.
36. Zha W, Zha BS, Zhou F, Zhou H, Wang G, (2012) The Cellular Pharmacokinetics of HIV Protease Inhibitors: Current Knowledge and Future Perspectives. Curr Drug Metab.
37. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL, (2005) Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33: 764-770.
38. Profit L, Eagling VA, Back DJ, (1999) Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors Author. Aids 13: 1623-1627.
39. Shitan N, Tanaka M, Terai K, Ueda K, Yazaki K, (2007) Human MDR1 and MRP1 recognize berberine as their transport substrate. Biosci Biotechnol Biochem 71: 242-245.
40. Richter M, Gyemant N, Molnar J, Hilgeroth A, (2004) Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors Author. Pharm Res 21: 1862-1866.
41. Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, et al. (2008) Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier Author. AIDS Res Hum Retroviruses 24: 1147-1154.
42. Artursson P, Palm K, Luthman K, (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 27-43.
43. Zhang Y, Benet LZ, (1998) Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res 15: 1520-1524.
44. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, et al. (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-245.
45. Gupta A, Zhang Y, Unadkat JD, Mao Q, (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2) Author. J Pharmacol Exp Ther 310: 334-341.
46. Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, et al. (2010) Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65: 1672-1680.
47. Shen ZF, Xie MZ, (1993) [Determination of berberine in biological specimen by high performance TLC and fluoro-densitometric method]. Yao Xue Xue Bao 28: 532-536.
48. Liu YT, Hao HP, Xie HG, Lai L, Wang Q, et al. (2010) Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos 38: 1779-1784.